Has Steven Kelsen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $295 in general payments to Steven Kelsen, MD across 7 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Steven Kelsen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Steven Kelsen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Steven Kelsen, MD

Pulmonary Disease · Philadelphia, PANPI 1104814243

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Harmony Biosciences LLC at 58.1% of the total. That places this record below the midpoint for pulmonary disease clinicians in PA, where the typical reported total is $988.

$295in general payments, 2019–2025

Across 7 payments — averaging $42.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Harmony Biosciences LLC$171
Regeneron Healthcare Solutions, Inc.$67
Tactile Systems Technology Inc$26
Resmed Corp$15
Electromed, Inc.$14

$852,552in research payments, 2019–2025

Across 178 payments — averaging $4789.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$443K
Teva Pharmaceuticals USA, Inc.$169K
GSK$139K
Incyte Corporation$40K
Sanofi US Services Inc.$39K
Hoffmann-la Roche Limited$18K
plus $6K from 1 others

What the payments were for

Food & beverage$295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Harmony Biosciences LLC	2	$171
Regeneron Healthcare Solutions, Inc.	2	$67
Tactile Systems Technology Inc	1	$26
Resmed Corp	1	$15
Electromed, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Wakix$125

How this compares

$295 in reported general payments places this provider in the 30th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$8,248

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XolairOmalizumab	61	$242,504
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	108	$83,981
Breo ElliptaFluticasone/Vilanterol	77	$33,072
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	43	$22,421
Albuterol Sulfate HfaAlbuterol Sulfate	178	$5,344
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	25	$3,979
Epinephrine	11	$2,357
Roflumilast	19	$2,145
Ventolin HfaAlbuterol Sulfate	37	$2,018
Theophylline ErTheophylline Anhydrous	11	$1,493
Fluticasone Propionate	71	$768
Montelukast Sodium	68	$588
Alprazolam	35	$310
MethotrexateMethotrexate Sodium	12	$212
Famotidine	63	$189

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Philadelphia

Gerard CrinerPhiladelphia$657K
Parth RaliPhiladelphia$314K
Steven GellerPhiladelphia$274K
Christopher ManleyPhiladelphia$262K
Jeffrey EdelsonPhiladelphia$233K
Benjamin WindPhiladelphia$168K
Boyd HehnPhiladelphia$157K
Gary AaronsonPhiladelphia$122K
Friedrich KueppersPhiladelphia$100K
Philip SilkoffPhiladelphia$88K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →